Felipe De Arriba De La Fuente-rekin lankidetzan egindako argitalpenak (14)

2024

  1. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2019

  1. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

2011

  1. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

    Blood, Vol. 118, Núm. 3, pp. 529-534

2004

  1. Trasplante de progenitores hematopoyéticos de sangre periférica en España: Análisis de coste

    Medicina Clinica, Vol. 123, Núm. 11, pp. 401-405

2003

  1. Massive intestinal infiltration in a patient with bone T-cell rich diffuse large B cell lymphoma.

    Haematologica, Vol. 88, Núm. 5

1999

  1. Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer

    Bone Marrow Transplantation, Vol. 23, Núm. 6, pp. 621-624

  2. Preleukapheresis peripheral blood CD34+ cells predict progenitor cell collection yield and the necessary number of procedures to undergo [2]

    Haematologica

1998

  1. Aplastic anaemia induced by ticlopidine after placement of coronary artery stents: Therapeutic role of granulocyte colony-stimulating factor

    Clinical Drug Investigation, Vol. 15, Núm. 3, pp. 261-262

  2. Bone marrow steady-state CD34+/CD71- cell content is a predictive value of rG-CSF-mobilized CD34+ cells

    Bone Marrow Transplantation, Vol. 21, Núm. 10, pp. 983-985

1997

  1. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells

    British Journal of Haematology, Vol. 96, Núm. 2, pp. 418-420

1996

  1. Coste económico del autotrasplante de progenitores hematopoyéticos

    Medicina Clinica, Vol. 106, Núm. 9, pp. 329-332

  2. Immune recovery after autologous or rhG-CSF primed PBSC transplantation

    European Journal of Haematology, Vol. 56, Núm. 5, pp. 301-307

1995

  1. The follow-up of the mobilization of circulating hematopoietic progenitor cells by granulocyte growth factor (G-CSF) using flow cytometry

    Medicina clínica, Vol. 104, Núm. 2, pp. 41-44